Which medication should be started at a low dosage and titrated slowly to minimize the risk of Stevens-Johnson syndrome?

Which medication should be started at a low dosage and titrated slowly to minimize the risk of Stevens-Johnson syndrome?

• A. Phenytoin
• B. Levetiracetam
• C. Lamotrigine
• D. Gabapentin

Answer: (C)

The main idea is that starting certain anticonvulsants carries a risk of a serious skin reaction, Stevens-Johnson syndrome, and this risk is strongly linked to how quickly the dose is increased. Lamotrigine has a well-established association with SJS if the dose is started too high or increased too rapidly. To lower that risk, it’s essential to begin at a very low dose and titrate up gradually over several weeks. Lamotrigine is effective for focal seizures and for mood stabilization in bipolar disorder, but its rash risk is most consequential early in therapy. The typical approach is a slow ramp: a small daily dose for a couple of weeks, then a higher but still gradual increase, with the goal of reaching a therapeutic level only after the body has had time to adjust. If the patient is also taking valproate, the drug’s levels rise more easily, so the titration must be even more gradual. Be vigilant for any signs of rash, fever, or mucous membrane involvement, as that can indicate SJS and requires immediate evaluation and stopping the medication. Other anticonvulsants can cause rash as well, but lamotrigine’s risk of SJS is the reason for the explicit slow-start strategy.

The main idea is that starting certain anticonvulsants carries a risk of a serious skin reaction, Stevens-Johnson syndrome, and this risk is strongly linked to how quickly the dose is increased. Lamotrigine has a well-established association with SJS if the dose is started too high or increased too rapidly. To lower that risk, it’s essential to begin at a very low dose and titrate up gradually over several weeks.

Lamotrigine is effective for focal seizures and for mood stabilization in bipolar disorder, but its rash risk is most consequential early in therapy. The typical approach is a slow ramp: a small daily dose for a couple of weeks, then a higher but still gradual increase, with the goal of reaching a therapeutic level only after the body has had time to adjust. If the patient is also taking valproate, the drug’s levels rise more easily, so the titration must be even more gradual.

Be vigilant for any signs of rash, fever, or mucous membrane involvement, as that can indicate SJS and requires immediate evaluation and stopping the medication.

Other anticonvulsants can cause rash as well, but lamotrigine’s risk of SJS is the reason for the explicit slow-start strategy.